EC Microbiology

Antisense oligonucleotides (oligos) have targeted regulatory proteins in both in vivo and in vitro prostate cancer models featuring both the LNCaP and PC-3 cell lines. In efforts to identify compensatory changes in the expression of non-targeted genes this study evaluated mono- and bispecific oligos capable of targeting and equally suppressing the expression of bcl-2 (an apoptosis inhibitor). Effects upon non-targeted genes could potentially lead to development of more phenotypically aggressive and metastatic tumors, as suggested by previous studies which have shown that oligo treated LNCaP cells compensate for diminished bcl-2 by suppressing caspase-3 (an apoptosis promoter) while enhancing the expression of AKT-1 (another apoptosis inhibitor). In addition, we found enhanced expression of the androgen receptor (AR), its p300 and IL-6 co-activators, polymerase transcription mediator MED-12, and growth regulating signal transducer STAT-3. This suggests that therapeutic approaches to restore apoptosis through suppres- sion of bcl-2 lead to altered protein expression of non-targeted genes not only involving apoptosis, but also androgen sensitivity and transcription. In addition, proteins associated with cell division as indicated by increased expression of the KI-67 proliferation antigen and mitosis regulating cyclin D1 are increased. The net result is an altered pattern of gene expression often associated with more aggressive and proliferative tumors.

To further evaluate adaptive compensatory mechanisms related to tumor resistance, aggression and proliferation we now evalu- ate the level of gene expression associated with producing fusion proteins and transcription factors which lead to the increased chro- mosomal instability associated with aggressive tumors. We now evaluate TMPRSS22, ERG and FLI-1 for changes in their expression. Fusion proteins formed from TMPSS22 and ERG are found in 40-80% of human prostate tumors, and ERG over expression is thought to disrupt AR signaling contributing to the development of androgen independent tumors. FLI-1 is a transcription factor associated with ETS expression and with the gene fusions increasingly found to be associated with development and progression of prostate cancer.

Keywords: Antisense; bcl-2; Prostate Cancer; Gene Therapy; Compensation

1. Rubenstein M., et al. “Inhibition of bcl-2 by antisense oligonucleotides is followed by a compensatory suppression of caspase-3 in LNCaP cells”. European Journal of Clinical and Medical Oncology2 (2011): 1-6.
2. Mu Z., et al. “Antisense bcl-2 sensitizes prostate cancer cells to radiation”. The Prostate4 (2005): 331-340.
3. Yip KW., et al. “Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer”. Clinical Cancer Research22 (2005): 8131-8144.
4. Yamanaka K., et al. “Novel bispecific antisense oligonucleotides inhibiting both bcl-2 and Bcl-xL expression induce apoptosis and enhance chemosensitivity in human androgen-independent prostate cancer cells”. Proceedings of the American Association for Cancer Research 45 (2004): 2930.
5. Rubenstein M., et al. “Additional compensatory mechanisms -altering antisense oligonucleotide suppression of Bcl-2: Effects upon AKT-1 and STAT.-3”. In Vivo5 (2014): 867-870.
6. Rubenstein M., et al. “In LNCaP cells enhanced expression of the androgen receptor compensates for bcl-2 suppression by antisense oligonucleotides”. Therapeutic Advances in Urology2 (2011): 73-79.
7. Rubenstein M., et al. “In LNCaP cells enhanced expression of both androgen receptor and co-stimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2”. Therapeutic Advances in Urology6 (2011): 243-250.
8. Rubenstein M., et al. “Increased expression of the androgen receptor with p300 and IL-6 coactivators compensate for oligonucleotide suppression of bcl-2. No increased CREBBP or IL-4 expression”. Therapeutic Advances in Urology2 (2013): 85-93.
9. Rubenstein M., et al. “Following inhibition of BCL-2 by antisense oligonucleotides compensatory suppression of apoptosis involves the direct signal transduction pathway of LNCaP cell”. Online Journal of Apoptosis1 (2015): 1-10.
10. Rubenstein M., et al. “Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3”. Medical Oncology3 (2013): 599.
11. Rubenstein M., et al. “No compensation in VEGF expression follows antisense suppression of bcl-2 activity”. In Vivo6 (2012): 937-940.
12. Rubenstein M., et al. “In LNCaP inhibition of bcl-2 by nucleotides results in compensatory changes involving apoptosis, transcription and immunoregulation”. Enliven: Journal of Genetic, Molecular and Cellular Biology1 (2014): 001.
13. Kausch I., et al. “Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo”. International Journal of Cancer5 (2003): 710-716.
14. Wang R., et al. “Antisense Ki-67 cDNA transfection reverses the tumorigenicity and induces apoptosis in human breast cancer cells”. Cancer Investigation8 (2008): 830-835.
15. Rubenstein M., et al. “Synthesis of branched antisense oligonucleotides having multiple specificities: Treatment of hormone insensitive prostate cancer”. Medical Hypotheses6 (2006): 1375-1380.
16. Rubenstein M and Guinan P. “Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of Bcl-2 in LNCaP cells”. In Vivo4 (2010): 489-493.
17. Rubenstein M., et al. “Increased prostate specific membrane antigen expression in LNCaP Cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR”. Medical Oncology4 (2010): 1212-1218.
18. Rubenstein M., et al. “Bispecific oligonucleotides may induce interferon in LNCaP cells enhancing surface antigen expression: Effect of intra strand base pair complementarity”. In Vivo1 (2011): 61-67.
19. http://www.washingtonpost.com/business/studies-merck-drug-keytruda-effective-against-3-cancers/2015/04/19/01d94cfce6b4-11e4-8581- 633c536add4b_story.html
20. Oncogenex
21. Kling J. “Safety signal dampens reception for mipomersen antisense”. Nature Biotechnology4 (2010): 295-297.
22. American Cancer Society. Cancer Facts & Figures 2017. Atlanta: American Cancer Society (2017).